Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Coronary Heart Disease (CHD)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 12,301 (final count)
- Started
- Jun 11, 2019
- Main results expected
- Jul 25, 2025
- Fully finished
- Jul 25, 2025
- Results posted
- Jun 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
Measured over: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First
Measured over: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03872401 · record last updated 2026-06-25 · checked 2026-11-09 15:47 UTC